FTC Settles With Supplement Marketer In Prison From FDA Investigation
This article was originally published in The Rose Sheet
FTC has settlement with CellMark and CEO Derek Vest alleging advertising regulation violations in marketing CellAssure supplements to treat cancer-related malnutrition, at $248 for a month's supply, and Cognify for treatment-related cognitive dysfunction sold for $79.
You may also be interested in...
Prison sentence in DMAA supplement case; Abbott Nutrition flat on currency exchange; Lurie takes CSPI helm; and more news in brief.
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.